Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Jun Lu, Hua Zhong, Tianqing Chu, Xueyan Zhang, Rong Li, Jiayuan Sun, Runbo Zhong, Yuqin Yang, Mohammad Shah Alam, Yuqing Lou, Jianlin Xu, Yanwei Zhang, Jun Wu, Xiaowei Li, Xiaodong Zhao, Kai Li, Liming Lu, Baohui Han. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018

Member's Comments

No comment yet.

Related content which might interest you: Targeted therapy in non-small cell lung cancer Source: Breathe 2012; 8: 206-215 Year: 2012 Therapeutic options targeting angiogenesis in nonsmall cell lung cancer Source: Eur Respir Rev 2014; 23: 79-91 Year: 2014 Proliferative activity of non-small cell lung cancer after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 328s Year: 2005 Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021 Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer Source: Eur Respir J 2010; 36: 885-892 Year: 2010 C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Surgical treatment of nonsmall cell lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=170 Year: 2001 Biological therapies in nonsmall cell lung cancer Source: Eur Respir J , 49 (3) 1601520; DOI: 10.1183/13993003.01520-2016 Year: 2017 Changes of lung function in patients with non-small cell lung cancer tretaed by chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 771s Year: 2006 Anticancer treatment for advanced non-small cell lung cancer Source: Breathe 2011; 8: 124-133 Year: 2011 Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations Source: Eur Respir J 2015; 46: 19-21 Year: 2015 Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007 Enhanced FGFR signaling correlates with erlotinib/bevacizumab response in advanced non-squamous non-small cell lung cancer Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)? Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Effects of pretreatment prognostic factors and treatment on survival in advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 Radiotherapy in the treatment of nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 207–243 Year: 2009 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012